Axsome Therapeutics eyes approval after Phase III narcolepsy win
The company’s Phase III trial of AXS-12 showed results over placebo as the company looks towards filing a new drug application for its narcolepsy therapy.
27 November 2024
27 November 2024
The company’s Phase III trial of AXS-12 showed results over placebo as the company looks towards filing a new drug application for its narcolepsy therapy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.